| Views | |
|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 142 |
| May 2026 | June 2026 | July 2026 | August 2026 | September 2026 | October 2026 | November 2026 | |
|---|---|---|---|---|---|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 3 | 12 | 5 | 6 | 21 | 30 | 3 |
| Views | |
|---|---|
| Naletova_Pharmacoepidemiologic_25.pdf | 45 |
| Views | |
|---|---|
| United States | 39 |
| Canada | 21 |
| China | 4 |
| Australia | 3 |
| Germany | 3 |
| Indonesia | 3 |
| Armenia | 2 |
| United Kingdom | 2 |
| Netherlands | 2 |
| Portugal | 2 |
| Views | |
|---|---|
| Ottawa | 18 |
| Houston | 8 |
| Indianapolis | 7 |
| San Francisco | 6 |
| Mountain View | 4 |
| Sacramento | 3 |
| Ann Arbor | 2 |
| Dearborn | 2 |
| Jakarta | 2 |
| Aalsmeer | 1 |